Current Report Filing (8-k)
May 14 2021 - 9:01AM
Edgar (US Regulatory)
0001034842
false
0001034842
2021-05-13
2021-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2021
RIGEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
0-29889
|
|
94-3248524
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
|
|
|
1180 Veterans Boulevard
|
|
|
South San Francisco, CA
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (650) 624-1100
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Title of Each Class
|
|
Trading
Symbol(s)
|
|
Name of Each Exchange on Which
Registered
|
Common Stock, par value $0.001 per share
|
|
RIGL
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 13, 2021, Alison L. Hannah was appointed
to serve on our board of directors until her successor is elected and has qualified, or sooner in the event of her death, resignation
or removal. Ms. Hannah joins the class of directors whose term expires at the 2023 annual stockholders’ meeting.
As a non-employee director of Rigel, Ms. Hannah
will receive a yearly retainer of $50,000.
In addition to the cash compensation
referenced in the preceding paragraph, Ms. Hannah will receive stock option grants under our 2018 Equity Incentive Plan, as amended,
or the Plan. Option grants under the Plan are non-discretionary. Upon the date of her appointment, Ms. Hannah received an initial
option grant to purchase 80,000 shares of common stock on the terms and conditions set forth in the Plan. In addition, on the day
following each annual meeting of stockholders, Ms. Hannah will automatically receive an annual option to purchase 30,000 shares of
common stock and 25,000 restricted stock units, provided that she continues to serve as a non-employee member of our board of directors. Rigel has also entered
into its standard form of indemnification agreement with Ms. Hannah.
There are no arrangements or understandings between
Ms. Hannah and any other persons pursuant to which she was elected as a member of our board of directors. There are no family relationships
between Ms. Hannah and any director, executive officer, or any person nominated or chosen by us to become a director or executive officer.
Ms. Hannah is not a party to any current or proposed transaction with us for which disclosure is required under Item 404(a) of Regulation
S-K.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 14, 2021
|
RIGEL PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ Dolly A. Vance
|
|
Dolly A. Vance
|
|
Executive Vice President, General Counsel and Corporate Secretary
|
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Sep 2023 to Sep 2024